Circulating 25-hydroxyvitamin D and risk of endometrial cancer Cohort Consortium Vitamin D Pooling Project of Rarer Cancers

American Journal of Epidemiology

Volumn 172, Issue 1, 2010, Pages 36-46

  Zeleniuch Jacquotte, Anne ^a   Gallicchio, Lisa ^a   Hartmuller, Virginia ^a   Helzlsouer, Kathy J ^a   McCullough, Marjorie L ^a   Setiawan, V Wendy ^a   Shu, Xiao Ou ^a   Weinstein, Stephanie J ^a   Weiss, Jocelyn M ^a   Arslan, Alan A ^a   De Vivo, Immaculata ^a   Gao, Yu Tang ^a   Hayes, Richard B ^a   Henderson, Brian E ^a   Horst, Ronald L ^a   Koenig, Karen L ^a   Patel, Alpa V ^a   Purdue, Mark P ^a   Snyder, Kirk ^a   Steplowski, Emily ^a   Yu, Kai ^a   Zheng, Wei ^a   Hankinson, Susan E ^a   more..

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Case control studies; Endometrial neoplasms; Prospective studies; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D;

BLOOD; BODY MASS; CANCER; COHORT ANALYSIS; COMPARATIVE STUDY; HEALTH RISK; PUBLIC HEALTH; REGRESSION ANALYSIS; RISK FACTOR; VITAMIN;

ADULT; ARTICLE; BLOOD DONOR; BODY MASS; CANCER RISK; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; RACE; STRATIFIED SAMPLE; VITAMIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; CHINA; COHORT ANALYSIS; ENDOMETRIUM TUMOR; FINLAND; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; UNITED STATES; VITAMIN D DEFICIENCY;

ADULT; CASE-CONTROL STUDIES; CHINA; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; FINLAND; HUMANS; LOGISTIC MODELS; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 78549253331     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq114     Document Type: Article

References (41)

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2006 Incidence and Mortality Web-based Report. Atlanta, GA: National Cancer Institute, Centers for Disease Control and Prevention, US Department of Health and Human Services, 2010. (http://www.cdc.gov/uscs).
2. Parkin DM, Whelan SL, Ferlay J, et al., eds. Cancer Incidence in Five Continents. Lyon, France: IARC Scientific Publications; 2002.
3. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57(2):205-212.
4. Holick M. Vitamin D deficiency. N Engl J Med. 2007;357(3): 266-281.
5. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002;94(6):1867-1875.
6. Mohr SB, Garland CF, Gorham ED, et al. Is ultraviolet B irradiance inversely associated with incidence rates of endometrial cancer: an ecological study of 107 countries. Prev Med. 2007;45(5):327-331.
7. Barbone F, Austin H, Partridge EE. Diet and endometrial cancer: a case-control study. Am J Epidemiol. 1993;137(4):393-403.
8. Negri E, La Vecchia C, Franceschi S, et al. Intake of selected micronutrients and the risk of endometrial carcinoma. Cancer. 1996;77(5):917-923.
9. Salazar-Martinez E, Lazcano-Ponce E, Sanchez-Zamorano LM, et al. Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico. Int J Gynecol Cancer. 2005;15(5):938-945.
10. McCullough ML, Bandera EV, Moore DF, et al. Vitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature. Prev Med. 2008;46(4):298-302.
11. 3-1α-hydroxylase in human endometrial tissue. J Steroid Biochem Mol Biol. 2007;103(3-5):771-775.
12. Viganò P, Lattuada D, Mangioni S, et al. Cycling and early pregnant endometrium as a site of regulated expression of the vitamin D system. J Mol Endocrinol. 2006;36(3):415-424.
13. Vienonen A, Miettinen S, Bläuer M, et al. Expression of nuclear receptors and cofactors in human endometrium and myometrium. J Soc Gynecol Investig. 2004;11(2):104-112.
14. Uitterlinden AG, Fang Y, van Meurs JBJ, et al. Genetic vitamin D receptor polymorphisms and risk of disease. In: Feldman D, Pike JW, Glorieux FH, eds. Vitamin D. Elsevier Academic Press; 2005.
15. Sowers MR, Wallace RB, Hollis BW, et al. Parameters related to 25-OH-D levels in a population-based study of women. Am J Clin Nutr. 1986;43(4):621-628.
16. Sahota H, Barnett H, Lesosky M, et al. Association of vitamin D related information from a telephone interview with 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev. 2008; 17(1):232-238.
17. Webb AR, Pilbeam C, Hanafin N, et al. An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr. 1990;51(6):1075-1081.
18. Gallicchio L, Helzlsouer KJ, Chow W-H, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):10-20.
19. Ersfeld DL, Rao DS, Body JJ, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem. 2004;37(10):867-874.
20. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem. 2009;42(15):1549-1556.
21. Viechtbauer W. MiMa: an S-Plus/R function to fit meta-analytic mixed-, random-, and fixed-effects models. Maastricht, the Netherlands: Maastricht University; 2006. (http://www.wvbauer.com).
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
23. Cook LS, Weiss NS, Doherty JA, et al. Endometrial cancer. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 2006:1027-1043.
24. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134 (doi:10.1136/ bmj.39367.495995.AE).
25. McCullough ML, Weinstein SJ, Freedman DM, et al. Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):21-35.
26. Wortsman J, Matsuoka LY, Chen TC. Decreased bioavailability of vitamin D in obesity. (Erratum in Am J Clin Nutr. 2003;77(5):1342).
27. Am J Clin Nutr. 2000;72(3): 690-693.
28. Lacey JV Jr., Leitzmann MF, Chang SC, et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. (Erratum in Cancer. 2007;110(4):937).
29. Cancer. 2007;109(7): 1303-1311.
30. Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. Longterm use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol. 2007;197(2):139.e1-139.e7.
31. Finkle WD, Greenland S, Miettinen OS, et al. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States). Cancer Causes Control. 1995;6(2):99-102.
32. Wang Y, Jacobs EJ, McCullough ML, et al. Comparing methods for accounting for seasonal variability in a biomarker when only a single sample is available: insights from simulations based on serum 25-hydroxyvitamin D. Am J Epidemiol. 2009;170(1):88-94.
33. Lowe L, Hansen CM, Senaratne S, et al. Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Recent Results Cancer Res. 2003;164: 99-110.
34. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2001;9(1):45-59.
35. 3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol. 2002;83(1-5): 85-92.
36. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366(9484):491-505.
37. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008;88(6): 1519-1527.
38. Platz EA, Leitzmann MF, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004;15(3): 255-265.
39. Hankinson SE, Manson JE, Spiegelman D, et al. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev. 1995;4(6):649-654.
40. Toniolo P, Koenig KL, Pasternack BS, et al. Reliability of measurements of total, protein-bound, and unbound estradiol in serum. Cancer Epidemiol Biomarkers Prev. 1994;3(1): 47-50.
41. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Endogenous Hormones and Breast Cancer Collaborative Group. J Natl Cancer Inst. 2002;94(8): 606-616.